Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Regulatory trajectory With semaglutide off the shortage list, the legal basis for 503B bulk compounding has narrowed significantly
Relative contraindications may include significant cancer risk factors, bleeding disorders, and concurrent use of anticoagulant medications
This gives you and your doctor a starting point
Medical disclaimer This article is for educational information only
Key Takeaways Tirzepatide (Zepbound) produces greater average weight loss than semaglutide (Wegovy) across both clinical trials and the first direct head-to-head comparison, 20.9% versus 14.9% in separate Phase 3 trials, and 20.2% versus 13.7% in the SURMOUNT-5 trial published in the New England Journal of Medicine
